SAN DIEGO and SUZHOU, China, May 27, 2025 — Adagene Inc. (Nasdaq: ADAG), a company focused on transforming antibody-based therapy discovery and development, announced today that its Chief Strategy Officer, Mickael Chane-Du, will attend the Jefferies Global Healthcare Conference 2025 in New York, New York from June 3-5. He will participate in one-on-one investor meetings and a fireside chat.

Jefferies Global Healthcare Conference 2025

  • Fireside Chat Date: Thursday, June 5
  • Fireside Chat Time: 9:20-9:50 AM (Eastern Time)
  • Location: New York Marriott Marquis
  • Webcast:

A replay of the presentation will be available for at least 30 days in the section of Adagene’s website at .

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a clinical-stage, platform-driven biotechnology company dedicated to transforming the discovery and development of innovative antibody-based cancer immunotherapies. Adagene uses computational biology and AI to create novel antibodies that address unmet global patient needs. The company has established strategic collaborations with leading global partners to leverage its SAFEbody® precision masking technology across multiple cutting-edge approaches.

Adagene’s highly differentiated pipeline, powered by its proprietary Dynamic Precision Library (DPL) platform—comprising NEObody™, SAFEbody, and POWERbody™ technologies—features novel immunotherapy programs. The company’s SAFEbody technology is designed to improve the safety and tolerability of antibody therapeutics. It uses precision masking to shield the binding domain of the biologic therapy, enabling tumor-specific targeting of antibodies in the tumor microenvironment and minimizing off-target toxicity in healthy tissues.

Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody targeting a unique CTLA-4 epitope in regulatory T cells (Tregs) within the tumor microenvironment. ADG126 is currently undergoing phase 1b/2 clinical studies in combination with anti-PD-1 therapy, with a focus on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). The SAFEbody platform, validated by ongoing clinical research, can be applied to various antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.

For more information, please visit: .
Follow Adagene on ,  and .

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Investor Contacts:

Raymond Tam
Adagene

Bruce Mackle
LifeSci Advisors